PB272

January 11, 2017

Puma Adds More HER2-mutant Cervical-cancer Patients to PB272 Trial

News

Puma Biotechnology has added more cervical-cancer patients to its Phase 2 trial of PB272 (neratinib), a therapy that can be used alone or with other therapies to treat patients with ... Read more

Featured

Black Women in the South Have Highest U.S. Incidence of Cervical Cancer, Study Says

March 1, 2017

Synthetic Genomics, Advaxis Launch Venture to Produce Synthetic DNA for Immunotherapy Clinical Trials

June 12, 2017

Cue Biopharma Develops Its First Immunotherapy for Cervical Cancer

April 3, 2017

New Study to Assess ADXS-DUAL, Opdivo Immunotherapy Combo in Metastatic Cervical Cancer

May 31, 2017

Higher Doses of AXAL Vaccine Are Safe, Effective in Certain Types of Cervical Cancer, Says Advaxis

April 12, 2017

BioNews Services, LLC

3 W Garden St
Suite 700
Pensacola, FL 32502
Email: info@Bionews.com
Phone: +1-800-936-1363

About Us
Contact Us
Terms of Service
Privacy Policy

Disclaimer:

Cervical Cancer News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.